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Abstract Insulin resistance is a clinical condition shared
by many diseases besides type 2 diabetes (T2DM) such as
obesity, polycystic ovary syndrome (PCOS) and non-
alcoholic fatty liver disease (NAFLD). Experimental evi-
dence, produced over the years, suggests that metformin
has many benefits in the treatment of these diseases.
Metformin is a first-line drug in the treatment of over-
weight and obese type 2 diabetic patients, offering a
selective pathophysiological approach by its effect on
insulin resistance. Moreover, a number of studies have
established the favorable effect of metformin on body
weight, not only when evaluating BMI, but also if body
mass composition is considered, through the reduction of
fat mass. In addition, it reduces insulin resistance, hyper-
insulinemia, lipid parameters, arterial hypertension and
endothelial dysfunction. In particular, a new formulation of
metformin extended-release (ER) is now available with
different formulation in different countries. Metformin ER
delivers the active drug through hydrated polymers which
expand safe uptake of fluid, prolonging gastric transit and
delaying drug absorption in the upper gastrointestinal tract.
In addition, Metformin ER causes a small, but statistically
significant decrease in BMI, when added to a lifestyle
intervention program in obese adolescents. Because of the
suggested benefits for the treatment of insulin resistance in
many clinical conditions, besides type 2 diabetes, the
prospective exists that more indications for metformin
treatment are becoming a reality.
Keywords Metformin  Insulin resistance  PCOS 
NAFLD  Obesity
Introduction
Insulin resistance (IR) and metformin
During the postprandial state, insulin secretion by the
pancreatic b cells controls nutrient homeostasis by pro-
moting anabolic processes in many tissues. During the
fasting state, insulin secretion decreases and tissues are
acted upon by counter-regulatory hormones, in favor of
using fatty acids largely derived from adipocyte lipolysis
for the generation of ATP and maintenance of glucose
homeostasis. The substrate preferences for metabolic
adaptation, during the transit from the fasting to the post-
prandial state, are tightly controlled by insulin under
physiological conditions [1]. This adaptive transition
reflects the action of insulin in insulin-responsive organs,
while it is largely blunted in organs with IR preceding the
development of type 2 diabetes (T2DM) [2]. IR produces
different effects in different organs and tissues. In central
nervous system (CNS), IR causes obesity, since in humans,
appetite is increased by the action of insulin in the CNS and
the current data indicate that neuronal insulin signaling is
required for both body weight control and glucose
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homeostasis [3]. IR in adipose tissue is responsible for
hyperlipidemia, in fact, in normal condition, insulin pro-
motes fat cell differentiation, enhances adipocyte glucose
uptake and inhibits adipocyte lipolysis; when insulin action
is deficient in adipose tissue, adipocyte development is
tampered and lipids are not generated from carbohydrates
for storage. Adipose tissue is also an endocrine organ,
secreting cytokines and hormones, and fat expansion dis-
rupts a proper balance of cytokine and hormone generation,
promoting insulin resistance [4]. Insulin stimulates the
synthesis of glycogen, lipids and protein in the liver and
suppresses hepatic glucose production by inhibiting gluco-
neogenesis, thus controlling blood glucose and lipid
homeostasis, therefore hepatic insulin resistance generates
hyperglycemia [5]. IR in pancreas impairs b cell regener-
ation: recent studies have shown that insulin enhances
glucose-stimulated insulin secretion in healthy humans [6],
however, whether insulin may have a direct autocrine action
on b cells in promoting insulin secretion is unclear [7].
Skeletal muscle is an important fuel storage tissue for glu-
cose uptake, converting it to glycogen and triglycerides; this
process, stimulated by insulin, is impaired in the IR con-
dition [8]. Cardiac insulin resistance promotes heart failure:
the heart is an insulin-responsive and energy-consuming
organ that requires a constant fuel supply to maintain
intracellular ATP levels for myocardial contraction [9]. IR
in vascular endothelium promotes hypertension and dis-
rupts glucose homeostasis [10]. IR in bone impairs glucose
homeostasis acting on the synthesis of osteocalcin [11].
Metformin because of its efficacy, security profile, and
benefic cardiovascular and metabolic effects is the first
glucose-lowering agent of choice in the treatment of T2DM
together with lifestyle modifications [12]. Metformin
decreases hepatic glucose output lowering fasting glyca-
emia and increases glucose uptake in peripheral tissues.
Interest in the therapeutic use of metformin has been
sparked by the recognition of its pleiotropic actions on
several tissues, which are affected by IR and hyperinsuli-
nemia. Although the liver is the primary target organ,
metformin acts on a variety of tissues, namely skeletal
muscles, adipose tissue, endothelium and the ovary [13].
Metformin and other drugs for the IR therapy in other
diseases besides type 2 diabetes
Experimental evidence suggests that metformin may be
useful in some clinical conditions different from T2DM
[14]. Metformin offers a selective pathophysiological
approach by its effect on IR. It has been shown in a number
of studies that it improves clinical outcomes in type 2
diabetic patients via multiple biological effects: it has been
shown, also, to retain platelet antiaggregating effects, to
reduce the rate of formation of advanced glycation end
products (AGEs) and to decrease the cellular oxidative
reactions, thus demonstrating its vascular protective effect.
A number of studies have established the favorable effect
of metformin on body weight, IR, hyperinsulinemia, lipid
parameters, arterial hypertension, fibrinolysis, and endo-
thelial dysfunction. On this basis, metformin appears to
have a broad set of pharmacological properties, making the
drug potentially applicable even in non-diabetic situations
such as obesity, extreme insulin resistance with acanthosis
nigricans, polycystic ovary syndrome (PCOS) and the non-
alcoholic fat liver disease (NAFLD). Metformin has been
demonstrated in the Diabetes Prevention Program to have a
role in preventing the conversion of IGT to T2DM and to
be a drug with multiple therapeutic effects far beyond its
effect on lowering blood glucose in T2DM [15].
Obesity
After binding to its receptor and activating the b-subunit,
insulin is faced with two divergent pathways: one is
phosphatidylinositol 3-kinase (PI 3-K) dependent, while
the other is dependent upon activation of mitogen-activated
protein kinase (MAP-K). The former mediates most gluco-
metabolic and anti-apoptotic effects; the latter is linked to
liposynthetic, proliferative and mitogenic effects. In obese
patients, especially with T2DM, only the PI 3-K, but not
the MAP-K, is resistant to insulin stimulation: hence IR is
better defined as the gluco-metabolic insulin resistance.
The resulting ‘‘compensatory hyperinsulinemia’’ is an
unsuccessful attempt to overcome the inhibition of the
gluco-metabolic pathway at the price of unopposed stim-
ulation of the MAP-K pathway and the administration of
exogenous insulin might worsen the metabolic dysfunction.
As the preferential activation of the MAP-K pathway in
insulin-resistant patients has atherogenic and mitogenic
properties, this may lead to atherosclerosis and cancer.
Metformin, in addition, may carry out direct protective
action on human b cells, inasmuch as it improves both
primary and secondary endpoints through selective inhi-
bition of fatty acyl oxidation [16]. Many studies have
demonstrated that metformin is associated with weight
reduction in adults and the prevention or delay of T2DM
onset, in those individuals who are at increased risk.
However, consensus is lacking on intervention strategies
aimed at reducing this risk, as reported in a recent paper
which discusses the rationale and evidence for the use of
metformin in obese children and young people at high risk
of T2DM [17]. The available evidence indicates that, in the
short term, administration of metformin in addition to
lifestyle modification is relatively effective in reducing
BMI and hyperinsulinemia among obese adolescents,
without related morbidity, and displays an acceptable
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safety pattern. Nevertheless, its long-term impact is
unknown [18, 19]. In fact, metformin appears to be mod-
erately efficacious in reducing BMI and IR in hyperinsu-
linemic obese children and adolescents in the short term.
Larger, long-term studies in different populations are
needed to establish its role in the treatment of overweight
children [20]. Some authors concluded that a limited period
of such a treatment may help weight control and might be
used to encourage those children who have been refractory
to weight loss for continuing the non-pharmacological
programs. These results should be confirmed in studies
with a longer follow-up period [21, 22]. The combination
of diet and exercise followed by metformin in the early
phase of ‘‘IR’’ may reduce or delay both atherosclerosis
and its complications associated with diabetes. Prevention
therapy must begin much earlier than clinical diagnosis of
diabetes, aiming to initially lower blood insulin levels or IR
[23]. A recent metanalysis shows that metformin provides a
statistically significant, but modest reduction in BMI when
combined with lifestyle interventions over the short term in
obese children. In the context of other options for treating
childhood obesity, metformin has not been shown to be
clinically superior [24]. Metformin is a drug effective in
reducing weight in a naturalistic outpatient setting in
insulin-sensitive and insulin-resistant overweight and obese
patients [25]. The results of an old study demonstrated that
metformin contributes to a reduction in body weight, body
fat mass and waist circumference, improves insulin sensi-
tivity and decreases basal, total and stimulated insulin
secretion in obese subjects. Thus, metformin appears to be
an effective and well-tolerated drug in the treatment of
obesity in subjects with normal glucose tolerance, it
improves not only the BMI, but also the body composition
reducing fat mass [26]. A significant decrease in body
weight, BMI, percentage body fat, the sum of saturated
fatty acids in serum phospholipids and increase in insulin
sensitivity index were observed following a 20-week
treatment. These changes did not differ significantly
between the groups. The results of a recent study suggest
that treating obese adolescents with IR using metformin for
3 months is an option for patients without response to
traditional lifestyle change because metformin decreases
inflammatory activity, which is an etiological factor in
cardiovascular disease development [27]. Metformin has
no effect on blood pressure and blood glucose levels, but it
does reduce total cholesterol, abdominal obesity and
C-reactive protein levels in obese hypertensive patients
without diabetes. [28]. Metformin trials are heterogeneous,
but one large, good-quality trial showed a weight loss of
2.3 kg more in the intervention group. Weight loss treat-
ments did not improve health outcomes, but they were not
homogenous in treatment methodology and most trials
were not powered for outcomes such as death and
cardiovascular events. Weight loss treatment resulted in a
reduction in diabetes incidence in two large, good-quality
behavioral-based trials of diabetes prevention. Behavioral-
based treatment showed small positive effects on blood
pressure [29]. Moreover, metformin may improve sense of
satiety and decrease anxiety about food in some individuals
with Prader–Willi syndrome and early morbid obesity.
Positive response to metformin may depend on the degree
of hyperinsulinism and glucose intolerance. Anyway, the
results of this pilot study require further investigation [30].
Energy restriction rather than metformin treatment appears
to be responsible for the observed changes. The associa-
tions previously found in diabetics between insulin sensi-
tivity and phospholipid fatty acids may not be mediated by
metformin [31]. The benefic effect of alpha-lipoic acid in
reducing IR in obese patients is controversial: there are
positive results in animals and in vitro [32], but these
results were not confirmed in humans [33].
Polycystic ovary syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy among women in reproductive age, with a
prevalence of 5–15 % of the general population [34, 35].
PCOS is characterized by menstrual disturbances, anovu-
latory infertility and high levels of male hormones which
appear in the early reproductive years; obesity is often
associated with these signs and symptoms [36]. The path-
ogenesis of PCOS is not completely understood. It can be
defined as a multifactorial endocrine disorder in which
multiple genes are involved. Based on the clustering of
cases in families, PCOS is considered a heritable disorder
[37]. Genetic influences are suggested by a high prevalence
of PCOS or its features among first-degree relatives [38]. In
addition, in monozygotic twins, there is a greater concor-
dance rather than in dizygotic twins [39]. However, the
mode of inheritance is not clear. It is also now accepted that
some environmental factors may influence the clinical
expression of the disorder: the presence of obesity, for
example, often contributes to accelerate the onset of the
disease in women predisposed to develop it or aggravates its
clinical presentation in women who have a mild form of the
syndrome. Anyway, several studies have clearly shown that
IR plays a key role in the pathogenesis of PCOS and of its
metabolic and cardiovascular abnormalities [40, 41].
Burghen found higher insulin concentrations, at basal state
and under glucose stimulation, in women with PCOS rather
in women without PCOS of the same age and weight [42].
Other data suggest that affected women have a higher IR
[43], independently by obesity degree and by presence of
impaired glucose tolerance [44]. In PCOS, IR seems to be
related to an excessive constitutive phosphorylation of
serine b-subunit of the insulin receptor, by a serine–
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threonine kinase. The defect is selective, involving the
metabolic effects of insulin, but not mitogenic one [43].
Approximately 50 % of PCOS patients, both obese and
slim, display IR associated with hyperinsulinemia [45].
These women have a significantly higher prevalence of
biochemical and hirsutism than women with non-insulin-
resistent PCOS [41]. Furthermore, they develop more often
menstrual disturbances, have a lower ovulation rate and are
more often resistant to clomiphene treatment [46]. Anyway,
PCOS is not diagnosed in all obese women with IR [40].
Probably in same women, IR should be considered an
important factor in pathogenesis of PCOS, but not the pri-
mary defect causing this disease. Considering the key role
of IR in pathogenesis of PCOS and the coexistence of
reproductive and cardiometabolic abnormalities in the
context of the same disease, therapeutic management of
affected women is changed in the last years. Insulin-sensi-
tizing drugs (metformin, pioglitazone, D-chiro-inositol)
have been introduced as a therapeutic option in PCOS,
targeting reproductive and cardiometabolic abnormalities
on the basis of its action on the reduction of glucose levels
and the attenuation of IR [13]. Metformin exerts its prin-
cipal metabolic action and especially its gluco-regulatory
action upon the liver; anyway, it has pleiotropic actions on
several other tissues affected by IR such as the skeletal
muscles, the adipose tissue, the endothelium and the ovary.
The increase in insulin sensitivity occurs in women with
PCOS without diabetes [47]. Metformin has a direct effect
on steroidogenesis in ovarian cells and an indirect effect due
to the alleviation of insulin excess acting upon the ovary.
Studies on cultures of ovarian theca cells show that met-
formin reduces CYP 17 activity directly and through
reduction of insulin levels [48]. Hence, the primary trend of
theca cells to increase synthesis and secretion of androgens
is reduced using metformin in PCOS disease: it promotes
the suppression of D-4A production through reduction of
CYP 17 lyase activity rather than CYP 17 hydroxylase
activity [47, 49]. Moreover, a decrease of insulin levels
promotes the reduction of activity of other steroidogenetic
enzymes in these cells, such as 3b-HSD and P450scc.
Metformin has shown to reduce basal and FSH-stimulated
progesterone and estradiol production both in rat than in
cultured human granulosa cells from women with or with-
out PCOS [50] and metformin treatment was associated to a
decrease of steroidogenesis and aromatase protein expres-
sion and to a inhibition of granulosa cell proliferation [51].
In PCOS patients, long-term metformin treatment, may
increase ovulation, improve menstrual cyclicity [52, 53],
and reduce serum androgen levels [54]. A recent review
[55] summarizes the effects of long-term therapy with
metformin in women with PCOS. Metformin improves both
ovulation and pregnancy rates but it does not improve live
birth rates and miscarriage. The effect of metformin
treatment on ovulation and pregnancy rate is higher in non-
obese PCOS patients. The improvement of pregnancy rate is
linked to an improvement in menstrual pattern. Metformin
has a significant effect in reducing fasting insulin levels in
the non-obese women and it reduces serum testosterone
concentrations. Metformin has no effect on fasting glucose
levels, serum lipid profiles and on anthropometric param-
eters as BMI and waist circumference (WC); reduction in
blood systolic pressure has been observed. Metformin can
delay the progression of glucose intolerance in women with
PCOS [56]. A recent consensus anyway does not recom-
mend its routine use in the treatment of women with
anovulatory PCOS. The lifestyle modification should be the
first-line management approach and form an integral part of
managing obese PCOS women, with metformin being less
effective in these patients [57]. Some authors [58] suggest
that clomiphene remains the first-line ovulation induction
agent and metformin may be added as an alternative ovu-
lation induction agent for clomiphene-resistant obese
women with PCOS. Furthermore, metformin may be added
in patients with glucose intolerance or T2DM who do not
respond adequately to calorie restriction and lifestyle
changes. Even though it has been shown that metformin
treatment reduces testosterone levels, the effects on hir-
sutism and acne described in clinical trials are modest [54].
Hence, metformin is unlikely to completely replace com-
bined oral contraceptives as a first-line therapy for
hirsutism.
In respect to the use of other insulin-sensitizing drugs,
few trials are available. Use of pioglitazone in women with
PCOS is associated with an improvement of ovulation rate
and menstrual pattern, but not of endocrine parameters such
as testosterone, insulin, lipid profile and glucose levels.
Anyway, recent consensus recommended to avoid use of
thiazolidinediones in management of PCOS women [58].
Inositol is described as a second messenger system that
may exert an insulin-like effect on metabolic enzymes [59]:
for this reason, it has been used as insulin-sensitizing agent
in women affected by PCOS. Some studies reported an
improvement in insulin sensitivity and ovulatory function in
the women treated, both in the isoform D-chiro-inositol [60],
and in the isoform myo-inositol [61]. Anyway a meta-
analysis [55] of some studies shows any improvement in
ovulation rate, any effects on BMI and WC and any effects
on testosterone, fasting glucose and insulin levels and lipids
profile. So, its use is not recommended in PCOS women.
Since IR is also present in lean women with PCOS,
several studies have suggested that an increased oxidative
stress could concur to the presence of IR in these patients
[62]. The use of biological antioxidants has been therefore
proposed in the treatment of PCOS women. Alpha-lipoic
acid (ALA), which is synthesized by the liver, is a bio-
logical antioxidant and natural cofactor of mitochondrial
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dehydrogenase complexes. In vitro studies have provided
evidence that ALA can improve insulin sensitivity, acti-
vating two important molecules of the insulin signaling
pathway-insulin receptor substrate-protein and phosphati-
dylinositol 3-kinase [63]. Some authors observed an
improvement in insulin sensitivity with ALA therapy in
these women despite the absence of severe IR [64]. Prob-
ably ALA has also been involved in AMPK activation such
as metformin and thiazolidinediones [65]. Further studies
are necessary to understand the molecular pathways of
ALA and its possible use in the management of lean
insulin-resistant women with PCOS.
NAFLD
Non-alcoholic fatty liver disease (NAFLD) is the most
common liver disorder worldwide. NAFLD is a general
diagnosis which encompasses a spectrum of pathological
processes ranging from non-alcoholic fatty liver (NAFL or
simple steatosis) to non-alcoholic steatohepatitis (NASH),
fibrosis, cirrhosis, and hepatocellular carcinoma [66]. The
pathophysiology is thought to be a two-step process char-
acterized by the liver accumulation of triglycerides and free
fatty acids induced by IR and the subsequent hepatocytes’
injury due to the oxidative stress and to the release of
proinflammatory cytokines [67]. IR represents the main
pathogenic factor underlying these metabolic disorders.
Although the molecular mechanism is still unclear, free
fatty acids and triglycerides metabolites have been sug-
gested to act directly or via toll-like receptors 2 and 4,
inducing endoplasmic reticulum stress, mitochondrial
dysfunction, ROS production, impairment of liver protein
metabolism, inhibition of insulin signaling and activation
of several inflammatory pathways [68]. Moreover, steatosis
determined the release of factors called hepatokines which
play the role of key mediators in the pathogenesis of local
and systemic inflammation and in the further impairment of
peripheral insulin sensitivity [69]. The subsequent chronic
inflammatory condition induces the progression from ste-
atosis to more advance stages of liver damage [70]. Epi-
demiological studies reported a significant association
between NAFLD and conditions associated with IR, such
as obesity, T2DM, hyperlipidemia, hypertension, and
PCOS [71]. Due to the increased risk of cirrhosis and
hepatocellular carcinoma, NAFLD is expected to become
the leading indication for liver transplant by 2020 [72].
Recent evidences suggest that NAFLD may represent an
independent cardiovascular risk factor related to a signifi-
cant increased mortality compared to the general popula-
tion [70]. Considering the key role of IR in pathogenesis of
NAFLD, insulin-sensitizing drugs (such as metformin,
thiazolidinediones) have been investigated as a therapeutic
option.
Beneficial effects of metformin on NAFLD may be
related to the adenosine monophosphate-activated protein
kinase (AMPK) pathway. Upon activation, AMPK stimu-
lates activation of catabolic and inhibition of ATP-depen-
dent anabolic processes. Furthermore in the liver, AMPK
reduces gluconeogenesis by the phosphorylation of CREB-
binding protein (CBP) and the dissociation of the glu-
coneogenic CREB–CBP–TORC2 transcriptional complex
[67]. Moreover, metformin decreases cholesterol and fatty
acid synthesis and promotes malonyl-CoA carboxylase
activity through the inhibition of acetyl-CoA carboxylase
(ACC) and 3-hydroxy-3-methylglutaryl (HMG)-CoA
reductase [73]. More recently, data in vivo and in vitro
suggest that metformin prevents hepatic steatosis by reg-
ulating the expression of cellular mediators of lipid storage
[74]. However, data about improvement in liver enzymes
and hepatic histology during treatment with metformin in
patients with NAFLD/NASH are controversial. Several
open-label clinical studies [75–84] supported the beneficial
effects on serum aminotransferases levels [75], and on IR
markers [75, 76, 80–84] of NAFLD/NASH patients treated
for at least 6 months with metformin (dose ranging
1.4–2.0 g/day) alone or in association with vitamin E [94]
or lifestyle intervention [75, 78, 84]. Only three open-label
studies have found no benefits of metformin treatment on
aminotransferase levels and IR markers [85–87]. However,
only few studies shown an improvement in liver histology
[77, 78, 81, 83]. These results have not been confirmed by
the larger randomized clinical trials [76, 82, 85, 88] com-
paring metformin and lifestyle intervention with lifestyle
changes alone. Results in pediatric population were similar
to those of adults, thus supporting positive effects on bio-
chemistry liver profile and metabolic parameters, but not
on liver histology. The randomized multicenter and pla-
cebo-controlled TONIC trial (treatment of nonalcoholic
liver disease in children) failed to demonstrate in a large
sample of children the superiority of metformin to placebo
in attaining a sustained reduction of amino transferase
levels and significant improvement in histological features
[89].
A recent systematic review and meta-analysis concluded
that treatment with metformin for 6–12 months together
with lifestyle intervention did not show any significant
improvement in aminotransferases circulating levels or
liver histology [90]. Based on these results, the current
practice guidelines by the American Association for the
Study of Liver Diseases, American College of Gastroen-
terology, and the American Gastroenterological Associa-
tion do not recommend metformin as a treatment for
NAFLD [91].
Thiazolidinediones (TZD) which are selective ligands of
the nuclear transcription factor peroxisome proliferator-!
(PPAR-!) have been largely investigated in patients
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affected by NAFLD/NASH. Following the activation of
PPAR-!, these drugs can up-regulate fatty acid disposal
and ameliorate tissue insulin sensitivity. In addition, TZD
promote fatty acid uptake and storage in adipose tissue,
sparing other insulin-sensitive tissues, such as skeletal
muscle and the liver, thus reversing the down-regulation of
IRS-1 which leads to IR [92]. Results coming from
uncontrolled open-label trials [82, 93, 94] were confirmed
by larger controlled trials. A double-blind, placebo-con-
trolled study performed on impaired glucose-tolerant
(IGT)/T2DM patients, has shown that pioglitazone treat-
ment (30–45 mg/day) for 6 months significantly amelio-
rates aminotransferase levels (by 50 %), steatosis (by
54 %), IR markers (by 48 %), liver inflammation and
necrosis, but not fibrosis [95]. A similar trial conducted in
non-diabetic individuals affected by NASH revealed a
significant improvement in liver fibrosis together with liver
enzymes and histological necro-inflammatory markers
reduction after 12 months [96]. The PIVENS study, a
multicenter, placebo-controlled trial analyzed the efficacy
of pioglitazone (30 mg/day) versus placebo and vitamin E
in 247 non-diabetic patients with biopsy-proven NASH.
The primary endpoint defined as an improvement in his-
tological findings accordingly with the NAFLD Activity
Score [97] was achieved by 34 % of pioglitazone-treated
patients and 43 % of vitamin E-treated individuals in
comparison to 19 % of control subjects. Moreover, reso-
lution of NASH, a secondary endpoint has been detected in
a significantly higher number of patients receiving piog-
litazone versus placebo, despite a significant body weight
increase [98]. A recent meta-analysis including 4 ran-
domized clinical trials demonstrated that pioglitazone sig-
nificantly improves steatosis, hepatic flogosis, necrosis and
liver fibrosis [92].
Based on these results, the current practice guidelines by
the American Association for the Study of Liver Diseases,
American College of Gastroenterology, and the American
Gastroenterological Association suggest to evaluate the use
of pioglitazone to treat steatohepatitis only in patients with
biopsy-proven NASH, noting that long-term safety and
efficacy of pioglitazone in non-diabetic patients is not
completely established [91].
Conclusions
Certainly many studies suggested the benefit of the treat-
ment of insulin resistance in many clinical conditions
besides type 2 diabetes and it is desirable to have in the
future more indications overall for metformin. In particu-
lar, a new formulation of metformin extended-release (ER)
is now available with different formulation in the base on
the different countries. This was reached using a Gelshield
diffusion system that gives metformin a slower absorption
than IR with a maximum plasma concentration of 7 versus
3 h. Metformin ER releases the active drug through
hydrated polymers which expand safe uptake of fluid,
prolonging gastric transit and slowering drug absorption in
the upper gastrointestinal tract [99, 100]. In addition,
Metformin ER causes a small, but statistically significant
decrease in BMI when added to a lifestyle intervention
program in obese adolescents [101].
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